



November 7, 2025

Company Name: AnGes Inc.

Presentative: Ei Yamada, President & CEO

Notice Regarding Establishment of a New Research and Development Base in the United States by Our Consolidated Subsidiary

AnGes Inc. is pleased to announce that we have decided to establish a new research and development (R&D) base for our consolidated subsidiary, EmendoBio Inc. ("EmendoBio"), in California, USA, and to shift the core of its R&D activities from Israel to the United States, as outlined below.

On January 29, 2024, in our "Notice of Business Restructuring at Consolidated Subsidiary," we announced that EmendoBio's Israeli R&D subsidiary, Emendo Research and Development Ltd. ("Emendo R&D"), would transition from a labor-intensive R&D structure to a knowledge-intensive structure leveraging machine learning, and that we would reorganize its R&D framework accordingly.

In line with this decision, we have been downsizing Emendo R&D's operations in Israel while strengthening EmendoBio's capabilities in the U.S. for advancing genome-editing technologies. We have now decided to establish a new genome-editing R&D base in the United States and gradually transfer the R&D functions from Emendo R&D to this new facility.

The new R&D base will be located in Palo Alto, California. Of the 20 employees currently at Emendo R&D (as of the end of September 2025), some will continue their R&D work at the new U.S. site, and we also plan to hire additional personnel locally. Details regarding the scale, facilities, and organizational structure will be determined in due course.

Given that the United States is at the forefront of genome-editing research globally and hosts a large pool of researchers, we believe conducting EmendoBio's R&D in the U.S. will be highly beneficial for future development. Furthermore, as announced on January 15, 2025, in our "Notice Regarding Joint Research Agreement with Stanford University for Development of Novel Cancer Therapies Using Genome Editing," we expect that collaboration with Stanford University on cancer genome-editing therapies will progress more smoothly through this new arrangement.

Future plans for Emendo R&D will be determined in stages, in line with the progress of the new U.S. base.

We are currently reviewing the costs associated with this decision. At present, we estimate that expenses related to establishing the U.S. base and transferring operations from Emendo R&D will range from approximately JPY 800 million to JPY 1.5 billion for facility leasing and renovation, equipment and machinery, and NGS-related costs. Personnel expenses for the first year, along with IT infrastructure, regulatory compliance, maintenance, safety measures, operating costs, and contingency funds, are expected to range from approximately JPY 900 million to JPY 1.4 billion. Of these, the minimum initial costs required are estimated at JPY 1.0 billion to JPY 1.5 billion.

However, as this period will primarily involve preparations for opening the new base, there will be

(Note) This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.

no changes to our earnings forecast for fiscal year 2025. We will promptly disclose any matters requiring announcement as they are decided.

EmendoBio Inc. Announces Expansion of OMNI-A4™ Licensing Agreement with Anocca AB

New York, USA, 3 September 2025 – EmendoBio Inc. (EmendoBio), an innovative gene editing company focused on the discovery and engineering of novel CRISPR nucleases for the development of gene edited therapeutics, today announced the expansion of its OMNI-A4™ non-exclusive licensing agreement with Anocca AB (Anocca), a leading clinical-stage T-cell immunotherapy company.

The expanded agreement builds upon the successful foundation established in March 2024, under which EmendoBio licensed its OMNI-A4™ nuclease to Anocca to accelerate the manufacture and development of Anocca's deep pipeline of TCR-T cell therapies for difficult-to-treat solid cancers. Under the terms of the new agreement, Anocca will expand the use of the OMNI-A4™ nuclease to knock-out and knock-in genes to further enhance its TCR-T product candidates.

"This expansion represents a significant milestone in our partnership with Anocca," said Ei Yamada, Chief Executive Officer at EmendoBio. "By broadening the scope of our collaboration, we are supporting Anocca's development of focused TCR-T cell therapies to address unmet patient needs."

"We are pleased to expand our collaboration with EmendoBio, enabling Anocca to deliver further innovative products from our deep TCR-T cell therapy pipeline" said Reagan Jarvis, Co-Founder and CEO at Anocca.

The financial details of the expanded agreement have not been disclosed.

About EmendoBio

EmendoBio is a next-generation AI-based CRISPR gene editing company leveraging its proprietary technology to enable high precision gene editing, which is critical for the development of safe medical applications of genome editing. Driven by cutting-edge AI-based tools, novel gene editing strategies, and advanced protein engineering tools, EmendoBio's novel nuclease discovery platform broadens the targetable range of the genome, while its target-specific optimization platform enables highly precise editing with high efficiency.

EmendoBio's proprietary OMNI™ nucleases also are designed to reduce "off-target" effects, i.e., cleavage at locations other than the targeted genes. Achieving such pinpoint precision is a substantial challenge for genome editing therapies.

The capabilities of the OMNI™ technology platform, along with deep expertise in genomic medicine and protein engineering, provide EmendoBio with a unique advantage when addressing indications, including within hematology, cardiovascular, ophthalmology, oncology, and other disease areas.

View EmendoBio's service offerings at <https://www.emendobio.com>.

EmendoBio Inc.

Noa Wertheimer
noaw@emendobio.com